Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Brookfield Infrastructure Partners LP (BIP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Brookfield Infrastructure Partners LP — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Brookfield Infrastructure Partners LP trades at $37.65 (market cap $17.26B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.3× Brookfield Infrastructure Partners LP's market cap, and Brookfield Infrastructure Partners LP pays a 4.83% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | BIP | |
|---|---|---|
Market Cap | $39.89B | $17.26B |
Sector | Health | Industrials |
52-Week High | $491.22 | $40.08 |
52-Week Low | $278.09 | $29.81 |
Enterprise Value | $38.15B | $78.93B |
Dividend Yield | — | 4.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Brookfield Infrastructure Partners (BIP) trades at $37.65, up 0.97% today, with a bullish technical signal from moving averages. The stock shows mixed earnings performance but maintains strong cash flows and a 5% dividend yield. Recent news highlights its infrastructure assets as resilient to economic uncertainty, with accelerating growth despite a 15% year-to-date decline. Analyst consensus is strongly bullish with an $45.50 price target, citing undervaluation and AI data center tailwinds.
BIP offers attractive total return potential through dividend income and growth from inflation-linked contracts, but faces execution risks from high leverage and interest rate sensitivity. Near-term catalysts include Q2 2026 earnings on July 30, 2026, while misses in recent quarters and net income margin compression warrant caution for growth-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Brookfield Infrastructure Partners LP
Brookfield Infrastructure owns and operates high-quality global assets across utilities, transport, midstream, and data sectors. It focuses on generating stable, long-term cash flows from essential infrastructure.
Read more on BIP →
